A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XBIO SEC filings page.
Xenetic Biosciences, Inc. (XBIO) reported $3.0M in revenue over the twelve months to Sep 30, 2026, up 3.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Xenetic remains a development-stage business, but FY2025 paired 19.0% revenue growth with lower spending and operating losses.
Revenue grew19.0% in FY2025 while the operating loss narrowed to$2.8M , showing better absorption of the company’s cost base. SG&A fell 19.6% while R&D still equaled103.0% of revenue, so the 72.9-percentage-point operating-margin improvement reflects spending restraint alongside a still development-stage cost structure.
Accounting losses have not become self-funding operations: FY2025 net loss was
The FY2025 operating shortfall coincided with financing cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Xenetic Biosciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Xenetic Biosciences, Inc. held $7.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $2.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Xenetic Biosciences, Inc. scores 67/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Xenetic Biosciences, Inc. scores 39/100 on it among other emerging companies.
Xenetic Biosciences, Inc. spent $3.1M on research and development in fiscal year 2025, which was 52.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Xenetic Biosciences, Inc. scores 77/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Xenetic Biosciences, Inc. scores 52/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Xenetic Biosciences, Inc. scores 72/100 on it among other emerging companies.
Xenetic Biosciences, Inc.'s cash, cash equivalents and investments came to $7.9M at the end of fiscal year 2025, against $968K of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Xenetic Biosciences, Inc. scores 93/100 among other emerging companies.
Xenetic Biosciences, Inc. scores -31.17, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $199.9M against total assets of $8.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Xenetic Biosciences, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Xenetic Biosciences, Inc. reported a net loss of $2.7M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Xenetic Biosciences, Inc. generated $725K in revenue in Q3 2026. This represents a decrease of 29.4% from the same quarter a year earlier. Against the prior quarter it is up 9.8%.
Xenetic Biosciences, Inc. reported a net loss of $1.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Xenetic Biosciences, Inc. earned -$0.72 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Xenetic Biosciences, Inc. held $5.8M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Xenetic Biosciences, Inc.'s quarterly ROE was -38.4% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 25.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 23.1 percentage points.
Not reported for Q3 2026.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Xenetic Biosciences, Inc. invested $521K in research and development in Q3 2026. This represents a decrease of 31.2% from the same quarter a year earlier. Against the prior quarter it is down 5.7%.
Not reported for Q3 2026.
Not reported for Q3 2026.
XBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $725K-29.4% | $661K+12.0% | $807K+36.0% | $766K+18.1% | $1.0M+67.2% | $590K-18.8% | $593K+16.1% | $649K-3.4% |
| R&D Expenses | $521K-31.2% | $552K-15.9% | $661K-24.8% | $773K-25.8% | $756K+105.6% | $657K-29.7% | $879K-6.9% | $1.0M+6.8% |
| SG&A Expenses | $1.9M+138.4% | $1.1M+64.2% | $648K-1.4% | $616K-12.7% | $815K+9.3% | $658K-41.8% | $657K-21.4% | $706K-25.9% |
| Operating Income | -$1.7Mn/m | -$972Kn/m | -$502Kn/m | -$623Kn/m | -$545Kn/m | -$724Kn/m | -$942Kn/m | -$1.1Mn/m |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Net Income | -$1.7Mn/m | -$930Kn/m | -$456Kn/m | -$579Kn/m | -$510Kn/m | -$689Kn/m | -$903Kn/m | -$1.1Mn/m |
| EPS (Basic) | -$0.72 | -$0.41n/m | -$0.20n/m | -$0.22 | -$0.33n/m | -$0.45n/m | -$0.59n/m | -$0.68n/m |
| EPS (Diluted) | -$0.72 | -$0.41n/m | -$0.20n/m | -$0.22 | -$0.33n/m | -$0.45n/m | -$0.59n/m | -$0.68n/m |
| Diluted Shares (Avg) | 2M | 2M+48.8% | 2M+48.6% | N/A | 2M0.0% | 2M+0.1% | 2M+0.1% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Interest Expense.
XBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.3M+24.7% | $7.0M+30.2% | $7.9M+36.6% | $8.4M+21.2% | $5.1M-37.0% | $5.4M-40.7% | $5.8M-38.4% | $6.9M-34.9% |
| Current Assets | $6.0M+18.5% | $6.7M+24.3% | $7.6M+38.7% | $8.0M+22.2% | $5.1M-27.9% | $5.4M-33.2% | $5.5M-34.6% | $6.6M-31.3% |
| Cash & Equivalents | $5.8M+41.0% | $6.5M+35.4% | $7.3M+42.3% | $7.9M+27.9% | $4.1M-39.7% | $4.8M-34.5% | $5.2M-34.0% | $6.2M-31.4% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $1.9M+71.3% | $895K-0.9% | $958K+43.5% | $968K+8.2% | $1.1M+10.1% | $903K-43.1% | $668K-6.8% | $894K+10.5% |
| Current Liabilities | $1.9M+71.3% | $895K-0.9% | $958K+43.5% | $968K+8.2% | $1.1M+10.1% | $903K-43.1% | $668K-6.8% | $894K+10.5% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Equity | $4.4M+11.6% | $6.1M+36.5% | $7.0M+35.7% | $7.4M+23.1% | $4.0M-43.8% | $4.5M-40.2% | $5.1M-41.0% | $6.0M-38.7% |
| Retained Earnings | -$203.0Mn/m | -$201.3Mn/m | -$200.3Mn/m | -$199.9Mn/m | -$199.3Mn/m | -$198.8Mn/m | -$198.1Mn/m | -$197.2Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
XBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
XBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -239.8% | -147.1% | -62.2% | -81.3% | -53.0%+28.3pp | -122.8% | -158.8% | -169.4% |
| Net Margin | -233.8% | -140.7% | -56.6% | -75.6% | -49.7%+21.4pp | -116.8% | -152.2% | -162.5% |
| Return on Equity | -38.4%-25.5pp | -15.3%+0.2pp | -6.6%+11.1pp | -7.8%+9.7pp | -12.9%-6.7pp | -15.5%+1.6pp | -17.6%-3.9pp | -17.5%-5.6pp |
| Return on Assets | -26.8%-16.8pp | -13.3%-0.5pp | -5.8%+9.8pp | -6.9%+8.4pp | -10.1%-4.6pp | -12.9%+1.2pp | -15.6%-2.9pp | -15.3%-4.2pp |
| Current Ratio | 3.15-1.4x | 7.43+1.5x | 7.93-0.3x | 8.32+0.9x | 4.56-2.4x | 5.93+0.9x | 8.20-3.5x | 7.37-4.5x |
| Liabilities-to-Equity | 0.43+0.2x | 0.15-0.1x | 0.140.0x | 0.130.0x | 0.28+0.1x | 0.200.0x | 0.130.0x | 0.15+0.1x |
| Asset Turnover | 0.11-0.1x | 0.090.0x | 0.100.0x | 0.090.0x | 0.20+0.1x | 0.110.0x | 0.100.0x | 0.090.0x |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Xenetic Biosciences, Inc. XBIO | FY2025 | $3.0M | -$2.7M | -90.1% | $3.3M | 67/100 |
| Aprea Therapeutics, Inc. APRE | FY2025 | N/A | -$12.6M | N/A | $3.2M | — |
| NuCana plc NCNA | FY2025 | N/A | -$39.5M | N/A | $3.6M | — |
| Imunon, Inc. IMNN | FY2026 | N/A | N/A | N/A | $3.5M | — |
| Liminatus Pharma, Inc. LIMN | FY2025 | N/A | -$10.2M | N/A | $3.4M | — |
| Azitra Inc AZTR | FY2025 | $0 | -$11.0M | N/A | $3.1M | — |
Where Xenetic Biosciences, Inc. Ranks
Frequently Asked Questions
Xenetic Biosciences, Inc. (XBIO) reported $3.0M in total revenue for fiscal year 2025. This represents a 19.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Xenetic Biosciences, Inc. (XBIO) revenue grew by 19.0% year-over-year, from $2.5M to $3.0M in fiscal year 2025.
No, Xenetic Biosciences, Inc. (XBIO) reported a net loss of $3.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $2.7M, with a net profit margin of -90.1%.
Xenetic Biosciences, Inc. (XBIO) had an operating margin of -95.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Xenetic Biosciences, Inc. (XBIO) had a net profit margin of -90.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Xenetic Biosciences, Inc. (XBIO) has a return on equity of -36.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Xenetic Biosciences, Inc. (XBIO) recorded an outflow of $2.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Xenetic Biosciences, Inc. (XBIO) had $8.4M in total assets as of fiscal year 2025, including both current and long-term assets.
Xenetic Biosciences, Inc. (XBIO) invested $3.1M in research and development during fiscal year 2025.
Xenetic Biosciences, Inc. (XBIO) had a current ratio of 8.32 as of fiscal year 2025, which is generally considered healthy.
Xenetic Biosciences, Inc. (XBIO) had a liabilities-to-equity ratio of 0.13 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Xenetic Biosciences, Inc. (XBIO) had a return on assets of -32.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Xenetic Biosciences, Inc. (XBIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $3.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Xenetic Biosciences, Inc. (XBIO) trades at 1.1x sales, its market capitalization divided by $3.0M revenue, trailing 12 months to September 30, 2026. The market capitalization is $3.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Xenetic Biosciences, Inc. (XBIO) held $7.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.3M over that year. Dividing the one by the other, the reported balance equals about 41 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Xenetic Biosciences, Inc. (XBIO) has an Altman Z-Score of -31.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Xenetic Biosciences, Inc. (XBIO) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Xenetic Biosciences, Inc. (XBIO) reported a net loss of $2.7M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Xenetic Biosciences, Inc. (XBIO) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.